ArticleRisk management and healthcare policy2025

Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China.

Hongting Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.